|
 Revenue rose 8.6 percent to $5.4 billion in the second quarter,
topping Wall Street estimates of $5.15 billion, as demand increased
for its drugs including Trulicity, Cyramza and Humalog.
Lilly resumed earnings growth last year after three years of
tumbling sales due to weak demand for its key products amid
competition from generic products.
The 140-year-old U.S. drugmaker said its net income rose 24.5
percent to $747.7 million, or 71 cents per share, in the quarter
ended June 30.
Excluding special items, Lilly earned 86 cents per share, in line
with the average analyst estimate, according to Thomson Reuters
I/B/E/S.
(Reporting by Natalie Grover in Bengaluru; Editing by Sriraj
Kalluvila and Kirti Pandey)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
 |
